A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Phase 4CompletedNCT02020512

Allergan87 enrolled

Overview

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

0.03% BimatoprostDRUG

0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension * No use of Lumigan® in the past 3 months Exclusion Criteria: * Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months

Locations (1)

Unnamed facility

Guangzhou, China

Outcomes

Primary Outcomes

Change From Baseline in Intraocular Pressure (IOP) in the Study Eye

IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).

Time frame: Baseline, Week 5

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.